LXRX
Lexicon Pharmaceuticals, Inc.
There isn't enough reported data to score LXRX yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
LXRX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
LXRX's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
LXRX PE Valuation
LXRX has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
LXRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect LXRX's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
LXRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.14 | +$0.04 |
| Q2 2026 | -$0.15 | +$0.17 |
| Q1 2026 | -$0.07 | +$0.43 |
| Q4 2025 | -$0.14 | +$0.49 |
| Q3 2025 | -$0.18 | +$0.57 |
| Q2 2025 | -$0.32 | +$0.46 |
| Q1 2025 | -$0.50 | +$0.33 |
| Q4 2024 | -$0.63 | +$0.17 |
LXRX is still losing money, but far less than before: $0.14 per share over the past year, against $1.05 at its worst in late 2020.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over LXRX on earnings quality, reporting a profit while its opponent remains loss making.
LXRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11.3M | -21% |
| Q2 2026 | $692K | -98% |
| Q1 2026 | $21.1M | +1572% |
| Q4 2025 | $5.5M | -79% |
| Q3 2025 | $14.2M | +710% |
| Q2 2025 | $28.9M | +1653% |
| Q1 2025 | $1.3M | +12% |
| Q4 2024 | $26.6M | +3683% |
LXRX's revenue has slid since its 2025 peak: $11M last quarter, down 21% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -129% | -43 points |
| Q2 2026 | -3835% | -3848 points |
| Q1 2026 | -4.7% | +2030 points |
| Q4 2025 | -269% | -146 points |
| Q3 2025 | -86% | +3554 points |
| Q2 2025 | 13% | +3374 points |
| Q1 2025 | -2035% | +1977 points |
| Q4 2024 | -123% | +6534 points |
LXRX's operating margin was −129% last quarter, down 43 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over LXRX on profitability, with a higher operating margin.
LXRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$8.1M | +$15.8M |
| Q1 2026 | -$14.7M | +$29M |
| Q4 2025 | -$17.2M | +$4.7M |
| Q3 2025 | -$23.8M | +$30.1M |
| Q1 2025 | -$43.8M | +$11.4M |
| Q4 2024 | -$22M | +$28.6M |
| Q3 2024 | -$53.9M | -$12.2M |
| Q2 2024 | -$48.8M | -$10.5M |
LXRX has burned cash in almost every quarter: −$49M over the past year, against −$144M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over LXRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
LXRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.7% | +7.3M shares |
| 1 year | +22% | +81.6M shares |
| 3 years | +82% | +200M shares |
| 5 years | +205% | +299M shares |
| Available history | +319% | +339M shares |
LXRX has 445M diluted shares, up 22% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | $1.7M |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | $824,000 |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over LXRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
LXRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2021 | -1.8x | Net Cash |
| Q1 2020 | 1.9x | Healthy |
| Q4 2019 | 1.4x | Healthy |
LXRX has more cash than debt.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
LXRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.4 | Neutral |
| Stochastic | 27.1 | Neutral |
LXRX's weekly RSI is 48 (neutral) and its Stochastic is 27 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
LXRX PE vs Healthcare Sector
| Metric | LXRX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
LXRX has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
LXRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.66 | 9.6% above |
| 20 week MA | $2.02 | 9.9% below |
| 50 week MA | $1.79 | 1.7% above |
| 100 week MA | $1.36 | 34% above |
| 200 week MA | $1.61 | 13% above |
LXRX has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
LXRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.26 | $3.49 | -18% |
| 2021 | $3.49 | $4.36 | +25% |
| 2022 | $4.36 | $1.95 | -55% |
| 2023 | $1.95 | $1.53 | -22% |
| 2024 | $1.53 | $0.77 | -50% |
| 2025 | $0.77 | $1.23 | +60% |
| 2026 YTD | $1.23 | $1.82 | +48% |
LXRX has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.